Research ArticleAccepted Article
Open Access
Pegloticase in combination with methotrexate in patients with uncontrolled gout: A multicenter, open-label study (MIRROR)
John K. Botson, John R.P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E. Weinblatt and Jeff Peterson
The Journal of Rheumatology September 2020, jrheum.200460; DOI: https://doi.org/10.3899/jrheum.200460
John K. Botson
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
John R.P. Tesser
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Ralph Bennett
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Howard M. Kenney
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Paul M. Peloso
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Katie Obermeyer
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Brian LaMoreaux
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Michael E. Weinblatt
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Jeff Peterson
Orthopedic Physicians Alaska, Anchorage, AK; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ; Arthritis Northwest, PLLC, Spokane, WA; Horizon Therapeutics, Lake Forest, IL; Horizon Therapeutics, Lake Forest, IL; Brigham and Women’s Hospital, Boston, MA; Western Washington Arthritis Clinic, Bothell, WA. Conflict of interest: Dr. Botson has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/speaker fees >10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. Dr. Tesser has received research grants/support from Horizon. Dr. Bennett has no financial relationships that pose a potential conflict of interest. Dr. Kenney has received research support from Horizon Therapeutics as a study site and principal investigator. He has also served as a speaker for Horizon Therapeutics. Dr. Peloso, Ms. Obermeyer, and Dr. LaMoreaux are employees of and own stock in Horizon Therapeutics. Dr. Weinblatt has received grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Lilly and Sanofi. He has received consulting fees >10k from Bristol Myers Squibb, Corona, and Lilly and <10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; he has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. Dr. Peterson has received research support from Horizon Therapeutics (study site/investigator). He has also served as an advisor and speaker for Horizon Therapeutics. Corresponding Author: John K. Botson, MD, RPh, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508. jbotson@opaak.com
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Pegloticase in combination with methotrexate in patients with uncontrolled gout: A multicenter, open-label study (MIRROR)
John K. Botson, John R.P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E. Weinblatt, Jeff Peterson
The Journal of Rheumatology Sep 2020, jrheum.200460; DOI: 10.3899/jrheum.200460
Accepted manuscript
Pegloticase in combination with methotrexate in patients with uncontrolled gout: A multicenter, open-label study (MIRROR)
John K. Botson, John R.P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E. Weinblatt, Jeff Peterson
The Journal of Rheumatology Sep 2020, jrheum.200460; DOI: 10.3899/jrheum.200460